Urogen pharma ltd. (URGN)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
REVENUES

-

-

-

0

-

1,128

1,455

8,984

8,620

8,158

0

0

0

COST OF REVENUES

-

-

-

-

-

1,803

2,090

1,330

1,012

600

0

0

0

GROSS (LOSS) PROFIT

-

-

-

0

-

-675

-635

7,654

7,608

7,558

0

0

0

OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES

56,159

49,297

40,668

40,761

39,038

36,934

32,230

28,277

23,655

18,697

0

0

0

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

0

-

-

-

0

-

-

-

-

-

-

-

-

GENERAL AND ADMINISTRATIVE EXPENSES

-

-

53,006

49,777

-

39,571

30,456

21,912

14,005

8,811

0

0

0

OPERATING LOSS

-125,606

-109,478

-93,656

-91,292

-85,973

-77,180

-63,321

-42,535

-30,052

-19,950

0

0

0

INTEREST AND OTHER INCOME, NET

4,111

4,332

4,022

3,229

0

-

0

0

-

-31

0

0

0

FINANCE INCOME, NET

-

-

-

-

-

-

-

-

0

-

-

-

-

NET LOSS

-121,495

-105,146

-89,889

-88,170

-83,719

-75,657

-62,027

-41,792

-29,965

-20,000

0

0

0

STATEMENTS OF COMPREHENSIVE LOSS
NET LOSS

-121,495

-105,146

-86,706

-82,480

0

-

0

0

-

-

-

-

-

OTHER COMPREHENSIVE INCOME:
UNREALIZED GAIN ON MARKETABLE SECURITIES

0

-

0

0

-

-

-

-

-

-

-

-

-

COMPREHENSIVE LOSS

-121,184

-104,870

-86,403

-82,199

0

-

0

0

-

-

-

-

-

NET LOSS PER ORDINARY SHARE BASIC AND DILUTED

1.79

-4.09

-1.06

-1.08

1.11

-3.26

-1.28

-1.14

0.88

-0.31

-0.02

-0.07

-1.74

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE

21,158

21,024

20,916

20,833

19,340

15,871

16,092

15,784

15,267

14,304

13,051

9,204

2,307